Ann: Strategic Investment from Sichuan Hebang Biotechnology, page-81

In the future, according to the contract signed between Hebang Hong Kong and AEV, AEV will be allocated to Hebang Hong Kong in two stages at an issue price of 0.006 Australian dollars per share, with a total subscription amount of Hebang Hong Kong of about 4.5 million Australian dollars. After completing the corresponding placement and the reorganisation of the board of directors and management, Hebang Hong Kong will absorb AEV as a holding subsidiary and provide it with interest-bearing loans to complete the development of the phosphate project as soon as possible.

https://www.hebang.cn/index/shows/35/625.html

straight from the hebang announcement but not in the Avenira one, interest bearing loans to complete the development of the phosphate project as soon as possible.

that seems like a rather glaring omission from the asx ann